CITATION REPORT List of articles citing

Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group

DOI: 10.1016/0735-1097(93)90403-n Journal of the American College of Cardiology, 1993, 22, 955-6

Source: https://exaly.com/paper-pdf/24188642/citation-report.pdf

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
475	Pharmacy In U.S. Aid. 1964 , 4, 592		
474	Do Digitalis Glycosides Still Have a Role in Congestive Heart Failure?. 1994 , 12, 51-62		4
473	Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment. 1994 , 72, 509-13		60
472	Inotropic agents for heart failure: what if digoxin increases mortality?. 1994 , 72, S92-9		7
471	Recent advances in cardiology. 1994 , 70, 257-74		
470	Clinical Practice Guidelines. 1994 , 272, 1374		18
469	Key references on heart failure. <i>Circulation</i> , 1994 , 90, 1093-100	16.7	
468	Myocardial phenotype changes in heart failure: cellular and subcellular adaptations and their functional significance. 1994 , 72, S10-7		12
467	Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1994 , 8, 761-8	3.9	2
466	Acronyms for heart failure trials. 1994 , 17, 576-8		
465	Is there a role for positive inotropic agents in congestive heart failure: focus on mortality. 1994 , 17, 641	-7	12
464	Digoxin for chronic heart failure: a review of the randomized controlled trials with special attention to the PROVED (Prospective Randomized Study of Ventricular Failure and the Efficacy of Digoxin) and RADIANCE (Randomized Assessment of Digoxin on Inhibitors of the angiotensin Converting		20
463	Enzyme) trials. 1994, 37, 49-58 Digoxin withdrawal in patients with heart failure. <i>Journal of the American College of Cardiology</i> , 1994, 24, 578-9	15.1	8
462	Reply. Journal of the American College of Cardiology, 1994 , 24, 578-579	15.1	7
461	Digoxin in eurhythmic heart failure: PROVED or "not proven"?. 1994 , 343, 128-9		13
460	Role of patient compliance in clinical pharmacokinetics. A review of recent research. 1994 , 27, 202-15		133
459	Congestive heart failure. 1994 , 96, 167-172		5

 $\,458\,$ $\,$ Positive inotropic drugs and drugs used in dysrhythmias. 1994, 18, 196-212 $\,$

457	A reexamination of the hemodynamic effects of digitalis relative to ventricular dysfunction. 1995 , 86, 94-101	5
456	Contemporary management of patients with heart failure. 1995 , 79, 1171-90	5
455	Progression of mild untreated heart failure during six months follow-up and clinical and neurohumoral effects of ibopamine and digoxin as monotherapy. DIMT Study Group. Dutch Ibopamine Multicenter Trial. 1995 , 75, 796-800	29
454	Angiotensin-converting enzyme inhibitors in the clinical setting of chronic congestive heart failure. 1995 , 75, 50F-55F	6
453	Heart failure: lessons learned over the past 25 years. 1995 , 18, 123-30	2
452	Medical Therapy and Prognosis in Chronic Heart Failure. 1995 , 13, 5-26	7
451	New Medical Therapies for Advanced Left Ventricular Dysfunction. 1995 , 13, 27-34	3
450	Congestive heart failure and pulmonary edema for the emergency physician. 1995, 13, 71-87	28
449	Is it safe to prescribe digoxin after acute myocardial infarction? Update on continued controversy. 1995 , 130, 1322-6	9
448	Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy. 1995 , 99, 629-35	95
447	Guidelines for the Evaluation and Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 1995 , 26, 1376-1398	1 287
446	Cardiac glycosides. Drug interactions of clinical significance. 1995 , 12, 97-109	16
445	Digoxin in the treatment of patients with chronic heart failure. Its place in therapy. 1995 , 7, 1-9	2
444	Clinical and economic factors in the treatment of congestive heart failure. 1995 , 7, 119-27	26
443	Does digoxin still have a role in eurhythmic heart failure?. 1995 , 6, 1-5	
442	Digoxin in chronic heart failure. 1995 , 345, 856	
441	Cardiovascular disease in elderly patients. 1996 , 71, 184-96	38

440	The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. 1996 , 132, 229-234		30
439	Digoxin therapy and survival in heart failure in sinus rhythm. 1996 , 55, 9-13		3
438	[Current status of treatment of chronic cardiac insufficiency]. 1996 , 17, 135-43		
437	Value of digoxin in heart failure and sinus rhythm: new features of an old drug?. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 813-9	15.1	32
436	ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). <i>Journal of the American College of Cardiology</i> , 1996 , 28, 1328-428	15.1	871
435	Inotropic agents in older patients with chronic heart failurecurrent perspectives. 1996 , 8, 90-8		1
434	Current guidelines for the treatment of congestive heart failure. 1996 , 51, 89-98		14
433	Novel drugs and current therapeutic approaches in the treatment of heart failure. 1996 , 51, 347-58		12
432	The Role of Digoxin in the Treatment of Chronic Congestive Heart Failure. 1996, 1, 259-264		
431	Management of Heart Failure Caused Primarily by Left Ventricular Systolic Dysfunction. 1996 , 9, 17-22		
430	The Economics of Cardiac Failure. Journal of the Royal Society of Medicine, 1996, 89, 9-12	2.3	1
429	Congestive heart failure. Towards a comprehensive treatment. 1996 , 17 Suppl B, 43-56		16
428	Optimal management of heart failure. 1996 , NS36, 92-107		
427	A cardiologist's perspective on evolving concepts in the management of congestive heart failure. 1996 , 36, 973-84		5
426	Evolving concepts regarding selection of patients for cardiac transplantation. Assessing risks and benefits. 1996 , 109, 223-32		13
425	Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators. 1996 , 77, 1078-82		14
424	The use of digitalis in heart failure. Current Problems in Cardiology, 1996, 21, 781-853	17.1	50
423	Positive inotropic therapy: an update and new agents. <i>Current Problems in Cardiology</i> , 1996 , 21, 521-81	17.1	8

422	Treatment of heart failure. 1996 , 239, 335-43	6
421	Progress in Interventional Cardiology. 1996 , 9, 355-358	
420	Cardioversion of atrial fibrillation. 1996 , 72, 126-126	
419	Cardioversion of atrial fibrillation. 1996 , 72, 126	
418	Left ventricular dysfunction and heart failure. Mechanistic and therapeutic distinctions. 1996 , 18, 559-68	
417	Refractory Heart Failure: A Therapeutic Approach. 1996 , 11, 121-148	4
416	End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis?. 1997 , 336, 575-6	36
415	Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. 1997 , 78, 564-8	68
414	The management of congestive heart failure. 1997 , 73, 194-200	8
413	Reflections on Recent Clinical Trials in Patients With Heart Failure and Those With Reduced Ventricular Function. 1997 , 2, 147-152	2
412	The effect of digoxin on mortality and morbidity in patients with heart failure. 1997 , 336, 525-33	2162
411	Digoxin and its related endogenous factors. 1997 , 34, 225-74	43
410	Is there an expanded role for digoxin in patients with heart failure and sinus rhythm? An antagonist viewpoint. 1997 , 31, 893-6	1
409	Is there an expanded role for digoxin in patients with heart failure and sinus rhythm? A protagonist viewpoint. 1997 , 31, 888-92	7
408	Recipient Selection and Management Before Cardiac Transplantation. <i>American Journal of the Medical Sciences</i> , 1997 , 314, 139-152	
407	The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. 1997 , 18, 736-53	296
406	Chapter 25 Cardiac glycosides. 1997 , 8, 501-518	1
405	Clinical Utility of Digoxin in Elderly Patients in Sinus Rhythm with Chronic Heart Failure. 1997 , 27, 406-409	

404	The AHCPR clinical practice guideline for heart failure revisited. 1997, 31, 1197-204		7
403	Current concepts in the treatment of congestive heart failure. 1997 , 88 Suppl 2, 2-6		8
402	The Effect of Drug Therapy on Quality of Life in Heart Failure. 1997 , 2, 93-106		1
401	Chronic Heart Failure. 1997 , 1, 185-196		3
400	When, and when not, to use digoxin in the elderly. 1997 , 10, 411-20		9
399	Digitalis Investigation Group (DIG) trial: a stimulus for further research. 1997 , 134, 3-12		53
398	Sarcoidosis in a pregnant woman. 1997 , 9, 78-86		8
397	Digoxin for patients with heart failure in sinus rhythm. 1997 , 350, 519		
396	Dose of digoxin prescribed in the UK compared with France and the USA. 1997, 349, 833-6		11
395	Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm?. <i>Journal of the American College of Cardiology</i> , 1997 , 29, 1206-13	15.1	107
394	Patients with mild heart failure worsen during withdrawal from digoxin therapy. <i>Journal of the American College of Cardiology</i> , 1997 , 30, 42-8	15.1	37
393	Effects of digoxin on time domain measures of heart rate variability in patients with stable chronic cardiac failure: withdrawal and comparison group studies. 1997 , 59, 29-36		9
392	Update in Cardiology. 1997 , 127, 388		1
391	Pharmacotherapy for systolic dysfunction: a review of randomized clinical trials. 1997 , 80, 14H-27H		33
390	Symptomatic improvement and reduced hospitalization for patients attending a cardiomyopathy clinic. 1997 , 20, 949-54		61
389	[Status of digitalis in therapy of acute and chronic heart failure]. 1997 , 92, 546-51		Ο
388	Medical treatment of heart failure: the Canadian Cardiovascular Society's Consensus Conference revisited. <i>Cardiovascular Drugs and Therapy</i> , 1997 , 10, 711-6	3.9	1
387	Cardiac Sodium Channels as Targets for New Inotropic Agents. <i>Heart Failure Reviews</i> , 1998 , 2, 173-193	5	6

386 Pharmacological Therapy of Cardiac Arrhythmias. **1998**, 6, 211-238

385	Effects of dichloroacetate in patients with congestive heart failure. 1998 , 21, 888-92	52
384	A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. Cardiac Arrhythmic Suppression Trial. Antiarrhythmic Versus Implantable Defibrillators. 1998 , 9, 864-91	37
383	Peripartum cardiomyopathy: a comprehensive review. 1998 , 178, 409-14	83
382	Are symptoms the most important target for therapy in chronic heart failure?. 1998, 41, 59-64	8
381	Heart failure in patients with preserved left ventricular systolic function: do digitalis glycosides have a role?. 1998 , 40, 357-69	27
380	Current concepts in the treatment of patients with heart failure. 1998, 7, 39-43	
379	[Heart failure: diagnosis and therapy]. 1998 , 93, 555-6	
378	Successes and failures of current treatment of heart failure. 1998 , 352 Suppl 1, SI19-28	71
377	15 years of heart-failure trials: what have we learned?. 1998 , 352 Suppl 1, SI29-33	37
376	Lung transplantation for pulmonary hypertension: patient selection and maintenance therapy while awaiting transplantation. 1998 , 12, 205-208	
375	Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme. Journal of the American	35
374	Diastolic effects of chronic digitalization in systolic heart failure. 1998 , 136, 688-95	О
373	Current medical therapy for advanced heart failure. 1998 , 135, S231-48	38
372	Current and novel pharmacologic approaches in advanced heart failure. 1998 , 135, S249-63	18
371	Optimizing therapy for complex or refractory heart failure: a management algorithm. 1998 , 135, S293-309	76
370	Temporal trends in pharmacotherapy for congestive heart failure at an academic medical center: 1990-1995. 1998 , 135, 367-72	33
369	Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. 1998 , 135, 389-97	13

368	A case series of hospitalized patients with elevated digoxin levels. 1998 , 105, 110-5		48
367	Digoxin use in congestive heart failure. Current status. 1998 , 55, 747-58		16
366	Carvedilol in the treatment of hypertensiona review of the clinical data base. 1998, 47, 67-80		5
365	Effect of Digoxin on Ventricular Remodeling and Responsiveness of beta-Adrenoceptors in Chronic Volume Overload. 1998 , 3, 281-290		3
364	Lung transplantation for pulmonary hypertension: patient selection and maintenance therapy while awaiting transplantation. 1998 , 10, 135-8		7
363	Digoxin revisited. 1998 , 91, 259-64		27
362	Digoxin toxicity: an evaluation in current clinical practice. 1998 , 158, 2444-9		44
361	Pharmacologic Management of Chronic Heart Failure: A Review. 1998 , 2, 168-190		2
360	The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. 1998 , 114, 787-92		263
359	Treatment of Heart Failure. 1998 , 343-368		
358	Innovations in the pharmacologic management of heart failure. 1998 , 9, 172-91; quiz 327-8		6
357	Human myocardial Na,K-ATPasequantification, regulation and relation to Ca. 1998 , 37, 335-45		11
356	Cost-effectiveness analysis in clinical practice: the case of heart failure. 1999 , 159, 1690-700		110
355	Failure of women's hearts. <i>Circulation</i> , 1999 , 99, 2334-41	16.7	119
354	A 75-year-old man with congestive heart failure. 1999 , 281, 2321-8		1
353	Clinical case studies in heart failure management. 1999 , 47, 239-47		
352	New information on the role of beta-blockers in cardiac therapy. <i>Cardiovascular Drugs and Therapy</i> , 1999 , 13, 469-77	3.9	3
351	Symptomatic systolic ventricular failure. 1999 , 1, 20-8		

350	Chronic Heart Failure. 1999 , 1, 231-242	3
349	Therapeutic range of digoxin's efficacy in heart failure: what is the evidence?. 1999 , 19, 1123-6	21
348	Cardiac glycosides in the next millennium. 1999 , 41, 247-54	35
347	Potential benefit of biventricular pacing in patients with congestive heart failure and ventricular tachyarrhythmia. 1999 , 83, 143D-150D	120
346	Digitalis. <i>Circulation</i> , 1999 , 99, 1265-70	220
345	Current and novel pharmacologic approaches in advanced heart failure. 1999 , 28, 227-42	1
344	Effectiveness of digitoxin versus trichlormethiazide/amiloride in congestive heart failure NYHA class II/III and sinus rhythm. <i>Cardiovascular Drugs and Therapy</i> , 1999 , 13, 233-41	1
343	Inappropriate use of digoxin in the elderly: how widespread is the problem and how can it be solved?. 1999 , 20, 223-30	12
342	HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunctionpharmacological approaches. 1999 , 5, 357-382	261
341	Effective management of complex heart failure. 1999 , 105, 17-24	4
340	Pharmacology of inotropic agents in infants and children. 2000 , 12, 57-79	20
339	HEART FAILURE SOCIETY OF AMERICA (HFSA) PRACTICE GUIDELINES. 2000 , 20, 495-522	24
338	Advances in the treatment of congestive heart failure: new approaches for an old disease. 2000 , 20, 787-804	22
337	Antiarrhythmic Impact of Anti-Ischemic, Anti-Failure and Other Cardiovascular Strategies. 2000 , 4, 194-205	2
336	[Perioperative risk and preoperative preparation of the cardiac patient for noncardiac surgery]. 2000 , 41, 283-91	1
335	[Drug therapy of heart failure]. 2000 , 41 Suppl 1, S2-12	2
334	Cost of treating heart failure in an Irish teaching hospital. 2000 , 169, 241-4	7
333	Community pharmacist outreach program directed at physicians treating congestive heart failure. 2000 , 57, 747-52	11

332	Evaluating quality of care for patients with heart failure. <i>Circulation</i> , 2000 , 101, E122-40 16.7	101
331	Drug treatment in heart failure. <i>BMJ: British Medical Journal</i> , 2000 , 320, 1188-92	33
330	Survival and prognosis: investigation of Crataegus extract WS 1442 in congestive heart failure (SPICE)rationale, study design and study protocol. 2000 , 2, 431-7	48
329	Schwangerschaftskardiomyopathie in der 22. SSW - Cardiomyopathy of Pregnancy at 22 Weeks' Gestation: A Case Report 2000 , 60, 388-391	
328	Effect of aging on the incidence of digoxin toxicity. 2000 , 34, 427-32	50
327	Current medical therapy for advanced heart failure. 2000 , 29, 16-32	29
326	Applied physiology: understanding cardiac failure. 2000 , 10, 284-288	
325	Cardiac afferents and neurohormonal activation in congestive heart failure. 2000 , 54, 242-53	16
324	Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure. 2000, 19, 638-43	36
323	Sudden death in heart failure patients: effects of optimized medical therapy. 2000 , 19, S32-7	1
322	Differential pharmacokinetics of digoxin in elderly patients. 2000 , 17, 353-62	62
321	Optimising management of patients with advanced heart failure: the importance of preventing progression. 2000 , 16, 87-106	2
320	DIGITALIS. 2000 , 73-78	
319	Surviving heart failure: Robert L. Frye lecture. 2000 , 75, 111-8	8
318	Mechanical cardiac support 2000: current applications and future trial design. June 15-16, 2000 Bethesda, Maryland. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 340-70	83
317	Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 806-13	155
316	Risks and benefits of a multidrug approach to mild-to-moderate heart failure. 2001 , 110 Suppl 7A, 63S-7S	3
315	Discussion. 2001 , 110, 67	3

(2001-2001)

314	Medical management of mild-to-moderate heart failure before the advent of beta blockers. 2001 , 110 Suppl 7A, 47S-62S	2
313	Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. 2001 , 142, 698-703	219
312	Mechanical cardiac support 2000: current applications and future trial design. 2001 , 20, 1-38	23
311	Perioperative cardiac complications. 2001 , 85, 1151-69, vi	13
310	[Evidence based medical treatment of heart failure]. 2001, 54, 715-34	6
309	Tratamiento de la insuficiencia card∃ca cr∃ica. 2001 , 8, 2010-2020	
308	The effect of chronic digitalization on pump function in systolic heart failure. 2001, 3, 593-9	2
307	Clinical trial designs for cytostatic agents. 2001 , 19, 3154-5	24
306	Heart failure therapy at the turn of the century. Heart Failure Reviews, 2001 , 6, 7-14 5	12
305	Treatment of congestive heart failure Œurrent status of use of digitoxin. 2001, 31, 10-17	4
304	What is the optimal medical management of ischemic heart failure?. 2001, 43, 433-55	19
303	Canine idiopathic dilated cardiomyopathy. Part II: pathophysiology and therapy. 2001 , 162, 182-95	26
302	Use of a clinical care map for the management of congestive heart failure in a community hospital. 2001 , 7, 37-42	3
301	What is the optimal medical management of ischaemic heart failure?. 2001 , 59, 135-58	5
300	Digitalis for treatment of congestive heart failure in patients in sinus rhythm. 2001, CD002901	3
299	Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice?. 2001 , 22, 488-96	122
298	Failing ageing hearts. 2001 , 22, 1978-90	24
297	Nutrition and Congestive Heart Failure. 2001 , 325-333	1

296	Inappropriate use of digoxin in older hospitalized heart failure patients. 2002, 57, M138-43		15
295	The effect of high dose digoxin on cytokines in healthy dogs. 2002 , 11, 261-3		
294	Lower serum digoxin concentrations in heart failure and reassessment of laboratory report forms. American Journal of the Medical Sciences, 2002, 324, 10-3	2.2	11
293	Treatment paradigms in heart failure. 2002 , 63, 80-7		1
292	Exercise and muscle strength training and their effect on quality of life in patients with chronic heart failure. 2002 , 4, 627-34		28
291	Clinical benefits of low serum digoxin concentrations in heart failure. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 946-53	5.1	110
29 0	Low-dose digoxin in patients with heart failure. Less toxic and at least as effective?. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 954-6	5.1	17
289	Cost and cost-effectiveness studies in heart failure research. 2002 , 143, 565-76		40
288	Use of ejection fraction (or lack thereof), morbidity/mortality and heart failure drug trials: a review. 2002 , 84, 119-32		11
287	Experiencia, ciencia y finedicina basada en pruebaslen Atencifi Pimaria. 2002 , 28, 302-304		3
286	What is wrong with positive inotropic drugs? Lessons from basic science and clinical trials. 2002 , 4, D43-D	49	4
285	Digoxin. 2002 , 44, 251-66		123
284	Predictive performance of serum digoxin concentration in patients with congestive heart failure by a hyperbolic model based on creatinine clearance. 2002 , 27, 257-65		14
283	2-Methoxy-3,8,9-trihydroxy coumestan: a new synthetic inhibitor of Na+,K+-ATPase with an original mechanism of action. 2003 , 66, 2169-76		21
282	Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. 2003 , 91, 18F-40F		85
281	Overview of the DIG trial. 2003 , 24, 269S-276S		4
280	Optimizing digoxin dosage: the long winding road. 2003 , 28, 347-8		
279	Treatment of congestive heart failure a neuroendocrine disorder. 2003 , 44, 154-60		5

278	Digoxin in heart failure. 2003 , 15, 447-52	1
277	The effect of digoxin on the quality of life in patients with heart failure. 2003 , 9, 4-12	41
276	Digoxin remains useful in the management of chronic heart failure. 2003, 87, 317-37	39
275	Drug therapy in chronic heart failure. 2003 , 79, 634-42	11
274	It cannot be cardiac failure because the heart is not enlarged on the chest X-ray. 2003, 5, 117-9	9
273	ProBNP for stratifying patients with heart failure. 2003 , 81, 239-8	2
272	Digoxin in heart failure and cardiac arrhythmias. 2003 , 179, 98-102	34
271	Selections from current literature: digoxin in chronic heart failure. 2004 , 21, 469-75	2
270	Digitalis therapy for patients in clinical heart failure. <i>Circulation</i> , 2004 , 109, 2942-6 16.7	68
269	A novel inexpensive murine model of oral chronic digitalization. 2004 , 31, 365-6	3
268	Digoxin in the management of cardiovascular disorders. <i>Circulation</i> , 2004 , 109, 2959-64 16.7	171
267	Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. 2004 , 10, 155-64	55
266	Age, functional capacity, and health-related quality of life in patients with heart failure. 2004 , 10, 368-73	117
265	Digitalis for treatment of congestive heart failure in patients in sinus rhythm. 2004 , CD002901	15
264	Inappropriate medications for elderly patients. 2004 , 79, 122-39	110
263	Anesthesiology: perioperative medicine or "when the anesthetic is a diuretic". 2004 , 16, 130-7	1
262	Alternative therapies for orthotopic heart transplantation. <i>American Journal of the Medical Sciences</i> , 2005 , 330, 88-101	3
261	Digitalis in heart failure! Still applicable?. 2005 , 94, 307-11	25

260	Chronic heart failure: developments and perspectives. 2005 , 20, 751-65		4
259	Pharmacotherapy of congestive heart failure in elderly patients. 2005 , 10, 85-94		5
258	Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. 2005 , 26, 778-93		203
257	Out-patient management of chronic heart failure. 2005 , 6, 1857-81		1
256	Digoxin may reduce the mortality rates in patients with congestive heart failure. 2005 , 64, 124-6		3
255	Whither Withering's Legacy? Digoxin's role in our contemporary pharmacopeia for heart failure. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 505-7	15.1	12
254	ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Journal of the American College of Cardiology, 2005, 46, e1-82	15.1	1119
253	Controversy in heart failure management: Digoxin use in the elderly. 2006 , 7, 581-6		7
252	Heart failure in patients with left ventricular systolic dysfunction. 2006 , 12, e38-57		18
251	What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial. 2006 , 12, 336-42		8
250	Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates2006. 2006 , 25, 1003-23		44
249	The use of digoxin in the treatment of arrhythmias and heart failure. 2006 , 1, 442-447		1
248	Use of Digoxin in the Treatment of Heart Failure. 17-29		
247	Association of Mortality Risk with High Serum Digoxin Concentrations. 2006 , 41, 343-347		2
246	Structure-activity relationship of wedelolactone analogues: structural requirements for inhibition of Na+, K+-ATPase and binding to the central benzodiazepine receptor. 2006 , 14, 7962-6		41
245	Pharmacological treatment of chronic heart failure. <i>Heart Failure Reviews</i> , 2006 , 11, 109-23	5	23
244	Use of digoxin in the treatment of chronic heart failure. 2006 , 21, 158-61		2
243	Optimal medical therapy for heart failure. 2006 , 48, 372-85		15

(2007-2006)

242	Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. 2006 , 27, 178-86	288
241	Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. 2006 , 24, 2505-12	902
240	Treatment of Advanced Heart Disease. 2006,	1
239	Contemporary use of digoxin in the management of cardiovascular disorders. <i>Circulation</i> , 2006 , 113, 2556-64	143
238	Surfen auf der Informationsflut. 2007 , 83, 202-219	
237	Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly. 2007, 3, 477-84	
236	Understanding the mechanisms and manifestations of digoxin toxicity helps in its management and treatment. 2007 , 23, 20-23	
235	Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly. 2007, 23, 141-53	1
234	Age- and gender-specific incidence of hospitalisation for digoxin intoxication. 2007, 30, 431-6	38
233	Pharmacologic therapy of chronic heart failure. 2007 , 7, 235-48	20
232	Chronic Heart Failure. 2007 ,	
231	Letters to the Editor. 2007 , 23, 188-189	2
230	. 2007,	6
229	References. 233-253	
228	Effects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure. 2007 , 100, 280-4	26
227	Withdrawal acute psychosis after corticosteroid discontinuation. 2007 , 34, 118-9	7
226	Frameworks for prescribing in comorbid illness. 2007 , 34, 117-8	4
225	Digoxin and mortality in atrial fibrillation: a prospective cohort study. 2007 , 63, 959-71	90

224	Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy. 2008 , 102, 1356-60	24
223	Medication withdrawal trials in people aged 65 years and older: a systematic review. 2008, 25, 1021-31	207
222	Management of Heart Failure. 2008,	1
221	Congestive heart failure in the pediatric patient with congenital heart disease. 2008 , 2, 33-45	1
220	Digoxin: current use and approach to toxicity. <i>American Journal of the Medical Sciences</i> , 2008 , 336, 423-8 _{2.2}	29
219	Noncardiac Surgery in the Patient with Cardiovascular Disease: Preoperative Evaluation and Perioperative Care. 2008 , 157-247	
218	Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy. 2009 , 2, 90-7	38
217	2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in	1178
216	Digoxin in management of heart failure in children: Should it be continued or relegated to the history books?. 2009 , 2, 149-52	14
215	Digoxin for the treatment of chronic and acute heart failure syndromes. 2009 , 11, 83-7	19
214	2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. <i>Circulation</i> , 2009 , 119, 1977-2016	1254
213	Digoxin: quo vadis?. 2009 , 2, 81-5	17
212	Digitoxin prolongs survival of female rats with heart failure due to large myocardial infarction. 2009 , 15, 798-804	7
211	Heart failure with preserved ejection fraction in older adults. 2009 , 122, 713-23	19
21 0	2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 1343-1382	187
209	Digitoxin elicits anti-inflammatory and vasoprotective properties in endothelial cells: Therapeutic implications for the treatment of atherosclerosis?. 2009 , 206, 390-6	19
208	2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in	1224
207	Collaboration With the International Society for Heart and Lung Transplantation. <i>Journal of the</i> Biological actions and metabolism of currently used pharmacological agents for the treatment of congestive heart failure. 2009 , 10, 206-19	13

206	Pharmacogenetically tailored treatments for heart disease. 2010 , 16, 2194-213		3
205	Peripartum cardiomyopathy. 2010 , 281, 183-8		30
204	Inotropic therapy for end-stage heart failure patients. 2010 , 12, 409-19		26
203	Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). 2010 , 16, 191-5		32
202	Treating Systolic Heart Failure. 2010 , 287-326		
201	Digoxin, Diuretics, and Vasodilators in Heart Failure. 2010 , 117-135		
200	[Digoxin: the results of the DIG study in the XXI century]. 2010 , 95, e108-11		1
199	Chronic Cardiac Failure. 2010 , 257-268		
198	Dental care for patients with heart failure: an update. 2010 , 141, 845-53		12
197	Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 392-406	15.1	272
197 196	therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a	15.1	272
	therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 392-406	15.1	,
196	therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 392-406 Digoxin therapy: A persisting interest despite contrary winds. 2010 , 103, 281-4 Improvements in health-related quality of life of patients admitted for heart failure. The HF-QoL	15.1	11
196	therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 392-406 Digoxin therapy: A persisting interest despite contrary winds. 2010 , 103, 281-4 Improvements in health-related quality of life of patients admitted for heart failure. The HF-QoL study. 2010 , 63, 668-76	15.1	3
196 195 194	therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 392-406 Digoxin therapy: A persisting interest despite contrary winds. 2010 , 103, 281-4 Improvements in health-related quality of life of patients admitted for heart failure. The HF-QoL study. 2010 , 63, 668-76 A fond farewell to the foxglove? The decline in the use of digitalis. 2010 , 16, 45-8	15.1	11 3 7
196 195 194	therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 392-406 Digoxin therapy: A persisting interest despite contrary winds. 2010 , 103, 281-4 Improvements in health-related quality of life of patients admitted for heart failure. The HF-QoL study. 2010 , 63, 668-76 A fond farewell to the foxglove? The decline in the use of digitalis. 2010 , 16, 45-8 Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. 2010 , 16, 475-539	15.1	11 3 7
196 195 194 193	therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 392-406 Digoxin therapy: A persisting interest despite contrary winds. 2010 , 103, 281-4 Improvements in health-related quality of life of patients admitted for heart failure. The HF-QoL study. 2010 , 63, 668-76 A fond farewell to the foxglove? The decline in the use of digitalis. 2010 , 16, 45-8 Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. 2010 , 16, 475-539 Section 7: Heart Failure in Patients With Reduced Ejection Fraction. 2010 , 16, e73-e97	15.1	11 3 7 231

188	Evolucili de la calidad de vida relacionada con la salud en pacientes ingresados por insuficiencia cardiaca. Estudio IC-QoL. 2010 , 63, 668-676	6
187	Comprehensive Cardiovascular Medicine in the Primary Care Setting. 2011,	
186	Chronic heart failure: current evidence, challenges to therapy, and future directions. 2011 , 11, 153-71	36
185	Mortality and morbidity of heart failure treated with digoxin. A propensity-matched study. 2011 , 65, 1250-8	18
184	Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. 2011 , 4, 578-88	31
183	Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine. 2011 , 10, 93-8	57
182	Post-trial period surveillance for randomised controlled cardiovascular studies: submitted protocols, consent forms and the role of the ethics board. 2011 , 37, 762-5	1
181	Heart failure treatment in the elderly. Expert Review of Cardiovascular Therapy, 2011 , 9, 1171-9 2.5	2
180	Effect of gender difference in management of heart failure patients in aseer, saudi arabia. 2011 , 12, 18-21	2
179	Nonsurgical therapy for heart failure. 2012 , 50, 1-21	
178	Can adult heart failure regimens be applied to children: what works and what does not?. 2012 , 27, 98-107	4
177	Positive inotropes in heart failure: a review article. 2012 , 4, 16-22	4
176	Digitalis toxicity: a fading but crucial complication to recognize. 2012 , 125, 337-43	43
175	Therapeutic ranges of serum digoxin concentrations in patients with heart failure. 2012 , 109, 1818-21	44
174	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1495-1539	233
173	Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. 2013 , 126, 701-8	42
172	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i> , 16.7 2013 , 128, e240-327	1927
171	The economics of heart failure. 2013 , 9, 93-106	16

170	Increased mortality among patients taking digoxinanalysis from the AFFIRM study. 2013, 34, 1481-8	191
169	Digoxin in advanced heart failure patients: a question of rhythm. 2013 , 32, 303-10	6
168	Standard nonspecific therapies in the management of pulmonary arterial hypertension. 2013, 34, 799-810	12
167	Digoxin in advanced heart failure patients: A question of rhythm. 2013 , 32, 303-310	3
166	200+ years of a misunderstood drug for treating chronic heart failure: digoxin, why and how should we continue using it?. 2013 , 168, 645-7	4
165	Pharmacological management of co-morbid conditions at the end of life: is less more?. 2013 , 182, 107-12	26
164	D. 2013 , 185-229	
163	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Journal of</i> 15.1 the American College of Cardiology, 2013 , 62, e147-239	4318
162	Digitalis, yesterday and today, but not forever. 2013 , 6, 511-3	8
161	Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. 2013 , 6, 525-33	52
160	Pharmacologic Management of Heart Failure in the Ambulatory Setting. 2013 , 241-269	1
159	2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice 16.7 guidelines. <i>Circulation</i> , 2013 , 128, 1810-52	2321
158	Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. 2013 , 15, 551-9	54
157	Temporary practice pause then resumption (TPPR) study design: an extension of the withdrawal study design to complementary and alternative medicine mind and body interventions (CAM-MABI). 2013 , 19, 833-7	1
156	Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). 2013, 77, 231-48	72
155	Role of digoxin in controlling the ventricular rate during atrial fibrillation: a systematic review and a rethinking. 2014 , 93	1
154	Interaction between digoxin and dronedarone in the PALLAS trial. 2014, 7, 1019-25	57
153	To dig or not to dig. 2014 , 127, 461-2	2

152	Seguimiento clīlico de una muestra contemporīlea de pacientes con fibrilaciīl auricular en tratamiento con digoxina: resultados del estudio AFBAR. 2014 , 67, 890-897		14
151	Outcomes of a contemporary sample of patients with atrial fibrillation taking digoxin: results from the AFBAR study. 2014 , 67, 890-7		7
150	Can medications be safely withdrawn in patients with stable chronic heart failure? systematic review and meta-analysis. 2014 , 20, 522-32		28
149	The previous use of digoxin does not worsen early outcome of acute coronary syndromes: an analysis of the ARIAM Registry. 2014 , 9, 759-65		9
148	Inotropes. Journal of the American College of Cardiology, 2014, 63, 2069-2078	15.1	108
147	A perspective on re-evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile. 2014 , 16, 483-93		19
146	Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure. 2014 , 34, 1121-31		7
145	The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1823-32	15.1	67
144	Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. 2014 , 127, 61-70		45
143	Digitalis for treatment of heart failure in patients in sinus rhythm. 2014 , CD002901		11
142	Is foxglove effective in heart failure?. 2015 , 33, 236-41		5
141	Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. 2015 , 7, 808-16		24
140	Digoxin therapy and associated clinical outcomes in the MADIT-CRT trial. 2015 , 12, 2010-7		18
139	Diagnosis and Management of Pulmonary Hypertension. Respiratory Medicine, 2015,	0.2	
138	Dronedarone-digoxin interaction in PALLAS: A foxglove connection?. 2015 , 2015, 4		1
137	The vulnerable phase after hospitalization for heart failure. 2015 , 12, 220-9		129
136	Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. 2015 , 17, 135-43		15
135	Digoxin in patients with atrial fibrillation and heart failure: A meta-analysis. 2015, 188, 99-101		26

134	Digoxin-associated mortality: a systematic review and meta-analysis of the literature. 2015 , 36, 1831-8	164
133	Gaps and Resemblances in Current Heart Failure Guidelines: A Clinical Perspective. 2015 , 11, 529-41	1
132	Digoxin: its role in contemporary medicine. 2015 , 91, 514-8	13
131	Digoxin, Diuretics, and Vasodilators in Patients with Heart Failure. 2015 , 47-75	
130	Actualizacili en el manejo de filmacos vasoactivos en insuficiencia cardiaca aguda y shock cardioglico y mixto. 2015 , 15, 8-14	
129	Comprehensive Management of High Risk Cardiovascular Patients. 2016,	1
128	Young at Heart: Pioneering Approaches to Model Nonischaemic Cardiomyopathy with Induced Pluripotent Stem Cells. 2016 , 2016, 4287158	4
127	Cardiac glycosides. 2016 , 117-157	
126	Addition of beta-blockers to digoxin is associated with improved 1- and 10-year survival of patients hospitalized due to decompensated heart failure. 2016 , 221, 198-204	5
125	Digoxin: The good and the bad. 2016 , 26, 585-95	66
125	Digoxin: The good and the bad. 2016 , 26, 585-95 A pharmacokinetic study of digoxin holiday dosing practice in Egypt: A prospective-randomized trial. 2016 , 54, 157-164	2
	A pharmacokinetic study of digoxin holiday dosing practice in Egypt: A prospective-randomized	
124	A pharmacokinetic study of digoxin holiday dosing practice in Egypt: A prospective-randomized trial. 2016 , 54, 157-164	2
124	A pharmacokinetic study of digoxin holiday dosing practice in Egypt: A prospective-randomized trial. 2016 , 54, 157-164 Digoxin for Worsening Chronic Heart Failure: Underutilized and Underrated. 2016 , 4, 365-7	2
124 123 122	A pharmacokinetic study of digoxin holiday dosing practice in Egypt: A prospective-randomized trial. 2016, 54, 157-164 Digoxin for Worsening Chronic Heart Failure: Underutilized and Underrated. 2016, 4, 365-7 Contemporary Controversies in Digoxin Use in Systolic Heart Failure. 2016, 13, 197-206	2 4 5
124 123 122	A pharmacokinetic study of digoxin holiday dosing practice in Egypt: A prospective-randomized trial. 2016, 54, 157-164 Digoxin for Worsening Chronic Heart Failure: Underutilized and Underrated. 2016, 4, 365-7 Contemporary Controversies in Digoxin Use in Systolic Heart Failure. 2016, 13, 197-206 Targeting digoxin dosing to serum concentration: is the bullseye too small?. 2016, 18, 1082-4 Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: A nationwide	2 4 5
124 123 122 121	A pharmacokinetic study of digoxin holiday dosing practice in Egypt: A prospective-randomized trial. 2016, 54, 157-164 Digoxin for Worsening Chronic Heart Failure: Underutilized and Underrated. 2016, 4, 365-7 Contemporary Controversies in Digoxin Use in Systolic Heart Failure. 2016, 13, 197-206 Targeting digoxin dosing to serum concentration: is the bullseye too small?. 2016, 18, 1082-4 Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: A nationwide propensity score matched study. 2016, 221, 944-50 Chronic Heart Failure Clinical Practice Guidelines' Class 1-A Pharmacologic Recommendations:	2 4 5 5

116	Heart Failure: Overcoming the Physiologic Dilemma Through Evidence-Based Practice. 2016, 51, 13-27	2
115	The Role of Positive Inotropic Drugs in the Treatment of Older Adults with Heart Failure and Reduced Ejection Fraction. 2017 , 13, 527-534	1
114	Ground Hog Day: Do We Need Another Analysis of Diuretic Dose and Outcomes in Heart Failure Patients?. 2017 , 23, 594-596	
113	Left ventricular ejection fraction as therapeutic target: is it the ideal marker?. <i>Heart Failure Reviews</i> , 2017 , 22, 641-655	13
112	Pharmacologic Therapy for Heart Failure With Reduced Ejection Fraction: Closing the Gap Between Clinical Guidelines and Practice. 2017 , 60, 187-197	10
111	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. 2017 , 47, 555-643	44
110	Digoxin and Heart Failure: Are We Clear Yet?. 2017 , 2, 333-345	
109	Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. 2018 , 199, 97-104	4
108	Acute Decompensated Heart Failure. 2018 , 33, 456-466	5
107	Systematic review of economic burden of heart failure. <i>Heart Failure Reviews</i> , 2018 , 23, 131-145 5	56
106	Management of advanced heart failure: a review. Expert Review of Cardiovascular Therapy, 2018 , 16, 775-₫.994	5
105	OBSOLETE: Role of Digoxin in Heart Failure. 2018 ,	
104	Role of Digoxin in Heart Failure. 2018 , 323-326	1
103	Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2019 , 74, 617-627	23
102	Is the Digitalis Leaf Still Withering?. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 628-630 15.1	
101	Does digoxin cause more harm than good?. 2019 , 11, 165-170	
100	Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study. 2019 , 21, 676-684	21
99	Pharmacotherapy in Heart Failure (I): Renin-Angiotensin-Aldosterone System (incl. ARNI), Diuretics, Digoxin and Statins. 2019 , 105-120	

98 Heart Failure. **2019**,

Ouestionable utility of digoxin in left-ventricular assist device recipients: A multicenter, retrospective analysis. 2019. 14, e0225628 96 Influence of OATP1B1 and OATP1B3 mutations and glomerular filtration rate on trough serum digoxin concentration in the Chinese population: A prospective cohort study. 2019, 98, e15088 95 2019, 98, e18144 96 Effect of digitalis level on readmission and mortality rate among heart failure reduced ejection fraction patients. 2019, 48, 22-27 97 Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia. 2019, 12, 66-75 98 Jogoxin and prognosis of heart failure in older patients with preserved ejection fraction: Importance of heart rate. Results from an observational and multicenter study. 2019, 60, 18-23 99 Evidence-Based Management of the Patient with Congestive Heart Failure. 2019, 449-465 90 Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. 2020, 520-548 80 Digitoxin Attenuates Heart Failure. Reduces Myocardial Hypertrophy, and Preserves the Calcium-Binding Proteins in Infarcted Rats. 2020, 25, 265-272 81 Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. 2020, 59, 1127-1146.e1 82 Digoxin, mortality, and cardiac hospitalizations in patients with heart failure with reduced ejection fraction. 2020, 7, 138-146 83 Digitoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and strial fibrillation: An AF-CHF analysis. 2020, 313, 48-54 84 With Competing Risk Analysis. 2021, 12, 564097 85 Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 2021, 9, 1-12 86 Eisen und Digitalis bei Herzinsuffizienz. 2021, 10, 302-309 87 Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. 2021, 8 88 Lesson und Digitalis bei Herzin			
digoxin concentration in the Chinese population: A prospective cohort study. 2019, 98, e15088 Hemodynamic effects of inotropic drugs in heart failure: A network meta-analysis of clinical trials. 2019, 98, e18144 Effect of digitalis level on readmission and mortality rate among heart failure reduced ejection fraction patients. 2019, 48, 22-27 Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia. 2019, 12, 66-75 pilogoxin and prognosis of heart failure in older patients with preserved ejection fraction: Importance of heart rate. Results from an observational and multicenter study. 2019, 60, 18-23 pilogoxin and prognosis of heart failure in older patients with preserved ejection fraction: Evidence-Based Management of the Patient with Congestive Heart Failure. 2019, 449-465 Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. 2020, 520-548 Digitoxin Attenuates Heart Failure, Reduces Myocardial Hypertrophy, and Preserves the Calcium-Binding Proteins in Infarcted Rats. 2020, 25, 265-272 Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. 2020, 59, 1127-1146.e1 Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction. 2020, 7, 138-146 Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. 2020, 313, 48-54 Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 2021, 9, 1-12 Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis. 2021, 12, 564097 Treatment of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic	97		1
Effect of digitalis level on readmission and mortality rate among heart failure reduced ejection fraction patients. 2019, 48, 22-27 Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia. 2019, 12, 66-75 Digoxin and prognosis of heart failure in older patients with preserved ejection fraction: Importance of heart rate. Results from an observational and multicenter study. 2019, 60, 18-23 Evidence-Based Management of the Patient with Congestive Heart Failure. 2019, 449-465 Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. 2020, 520-548 Digitoxin Attenuates Heart Failure. Reduces Myocardial Hypertrophy, and Preserves the Calcium-Binding Proteins in Infarcted Rats. 2020, 25, 265-272 Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. 2020, 59, 1127-1146.e1 Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction. 2020, 7, 138-146 Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. 2020, 313, 48-54 Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 2021, 9, 1-12 Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis. 2021, 12, 564097 Treatment and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. 2021, 3, Eisen und Digitalis bei Herzinsuffizienz. 2021, 10, 302-309 Association of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic	96		
fraction patients. 2019, 48, 22-27 Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia. 2019, 12, 66-75 pigoxin and prognosis of heart failure in older patients with preserved ejection fraction: Importance of heart rate. Results from an observational and multicenter study. 2019, 60, 18-23 principal Evidence-Based Management of the Patient with Congestive Heart Failure. 2019, 449-465 Evidence-Based Management of the Patient with Congestive Heart Failure. 2019, 449-465 Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. 2020, 520-548 Digitoxin Attenuates Heart Failure, Reduces Myocardial Hypertrophy, and Preserves the Calcium-Binding Proteins in Infarcted Rats. 2020, 25, 265-272 Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. 2020, 59, 1127-1146.e1 Digoxin Is associated with worse outcomes in patients with heart failure with reduced ejection fraction. 2020, 7, 138-146 Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. 2020, 313, 48-54 Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 2021, 9, 1-12 Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis. 2021, 12, 564097 Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. 2021, 8, Eisen und Digitalis bei Herzinsuffizienz. 2021, 10, 302-309 Association of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic	95		1
pigitoxin Attenuates Heart Failure, Reduces Myocardial Hypertrophy, and Preserves the Calcium-Binding Proteins in Infarcted Rats. 2020, 25, 265-272 Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. 2020, 59, 1127-1146.e1 Digoxin, mortality, and cardiac hospitalizations in patients with heart failure with reduced ejection fraction fraction and atrial fibrillation: An AF-CHF analysis. 2020, 313, 48-54 Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis. 2021, 12, 564097 Evidence-Based Management of the Patient with Congestive Heart Failure. 2019, 449-465 Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. 2020, 520-548 By Digitoxin Attenuates Heart Failure, Reduces Myocardial Hypertrophy, and Preserves the Calcium-Binding Proteins in Infarcted Rats. 2020, 25, 265-272 Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. 2020, 59, 1127-1146.e1 Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction. 2020, 7, 138-146 Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. 2020, 313, 48-54 7 Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 2021, 9, 1-12 Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis. 2021, 12, 564097 Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. 2021, 8, Eisen und Digitalis bei Herzinsuffizienz. 2021, 10, 302-309	94		2
proportance of heart rate. Results from an observational and multicenter study. 2019, 60, 18-23 proportion of the Patient with Congestive Heart Failure. 2019, 449-465 Evidence-Based Management of the Patient with Congestive Heart Failure. 2019, 449-465 Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. 2020, 520-548 proportion of Digoxin Attenuates Heart Failure, Reduces Myocardial Hypertrophy, and Preserves the Calcium-Binding Proteins in Infarcted Rats. 2020, 25, 265-272 Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. 2020, 59, 1127-1146.e1 proportion is associated with worse outcomes in patients with heart failure with reduced ejection fraction. 2020, 7, 138-146 proportion is associated with worse outcomes in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. 2020, 313, 48-54 Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 2021, 9, 1-12 Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis. 2021, 12, 564097 Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. 2021, 8. Eisen und Digitalis bei Herzinsuffizienz. 2021, 10, 302-309 Association of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic	93		9
Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. 2020, 520-548 By Digitoxin Attenuates Heart Failure, Reduces Myocardial Hypertrophy, and Preserves the Calcium-Binding Proteins in Infarcted Rats. 2020, 25, 265-272 Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. 2020, 59, 1127-1146.e1 Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction. 2020, 7, 138-146 Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. 2020, 313, 48-54 Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 2021, 9, 1-12 Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis. 2021, 12, 564097 Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. 2021, 8, Eisen und Digitalis bei Herzinsuffizienz. 2021, 10, 302-309 Association of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic	92		9
Digitoxin Attenuates Heart Failure, Reduces Myocardial Hypertrophy, and Preserves the Calcium-Binding Proteins in Infarcted Rats. 2020, 25, 265-272 Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. 2020, 59, 1127-1146.e1 Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction. 2020, 7, 138-146 Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. 2020, 313, 48-54 Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 2021, 9, 1-12 Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis. 2021, 12, 564097 Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. 2021, 8, Eisen und Digitalis bei Herzinsuffizienz. 2021, 10, 302-309 Association of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic	91	Evidence-Based Management of the Patient with Congestive Heart Failure. 2019 , 449-465	
Calcium-Binding Proteins in Infarcted Rats. 2020, 25, 265-272 Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. 2020, 59, 1127-1146.e1 1 Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction. 2020, 7, 138-146 Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. 2020, 313, 48-54 Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 2021, 9, 1-12 Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis. 2021, 12, 564097 Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. 2021, 8, Eisen und Digitalis bei Herzinsuffizienz. 2021, 10, 302-309 Association of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic	90	Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. 2020, 520-548	
Symptoms, Function, and Quality of Life. 2020, 59, 1127-1146.e1 87 Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction. 2020, 7, 138-146 86 Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. 2020, 313, 48-54 87 Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 2021, 9, 1-12 88 Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis. 2021, 12, 564097 89 Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. 2021, 8, 80 Eisen und Digitalis bei Herzinsuffizienz. 2021, 10, 302-309	89		1
57 fraction. 2020, 7, 138-146 86 Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. 2020, 313, 48-54 85 Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 2021, 9, 1-12 84 Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis. 2021, 12, 564097 85 Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. 2021, 8, 86 Eisen und Digitalis bei Herzinsuffizienz. 2021, 10, 302-309	88		1
with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. 2020, 313, 48-54 7 7 85 Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 2021, 9, 1-12 84 Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis. 2021, 12, 564097 85 Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. 2021, 8, 86 Eisen und Digitalis bei Herzinsuffizienz. 2021, 10, 302-309 87 Association of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic	87		4
Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis. 2021, 12, 564097 Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. 2021, 8, Eisen und Digitalis bei Herzinsuffizienz. 2021, 10, 302-309 Association of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic	86		7
With Competing Risk Analysis. 2021, 12, 564097 Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. 2021, 8, Eisen und Digitalis bei Herzinsuffizienz. 2021, 10, 302-309 Association of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic	85	Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 2021 , 9, 1-12	10
Lessons from Adult Trials. 2021, 8, Eisen und Digitalis bei Herzinsuffizienz. 2021, 10, 302-309 Association of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic	84		1
وع Association of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic	83		1
	82	Eisen und Digitalis bei Herzinsuffizienz. 2021 , 10, 302-309	
	81	Association of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic Heart Disease Patients With Heart Failure: A Retrospective Study. 2021 , 8, 711203	1

80	Therapeutics in Congestive Heart Failure: From Hemodynamics to Neurohormones. <i>Progress in Experimental Cardiology</i> , 2003 , 17-34		2
79	Heart Failure due to Left Ventricular Systolic Dysfunction. 2020 , 149-175		1
78	Epidemiology of heart failure. 1997 , 119-124		1
77	Acute and Chronic Heart Failure: Positive Inotropes, Vasodilators, and Digoxin. 2009, 160-197		2
76	Treatment of congestive heart failurecurrent status of use of digitoxin. 2001, 31 Suppl 2, 10-7		44
75	Recipient selection and management before cardiac transplantation. <i>American Journal of the Medical Sciences</i> , 1997 , 314, 139-52	2.2	16
74	Heart Failure due to Ischaemic Heart Disease: Epidemiology, Pathophysiology and Progression. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 33, S17-S29	3.1	14
73	Long-term results of the Spanish trial on treatment and survival of patients with predominantly mild heart failure. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 33, 733-40	3.1	8
72	Heart failure due to ischaemic heart disease: epidemiology, pathophysiology and progression. Journal of Cardiovascular Pharmacology, 1999 , 33 Suppl 3, S17-29	3.1	22
71	CardiologyII: Treatment of heart failure and atrial fibrillation and arrhythmias. <i>BMJ: British Medical Journal</i> , 1994 , 309, 1631-5		5
70	Bedside science reduces laboratory art. Appropriate use of physical findings to reduce reliance on sophisticated and expensive methods. <i>Circulation</i> , 1995 , 91, 2089-92	16.7	18
69	Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. <i>Circulation</i> , 1995 , 92, 3593-612	16.7	286
68	Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. <i>Circulation</i> , 1995 , 92, 1801-7	16.7	74
67	Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). <i>Circulation</i> , 1995 , 92, 2764-84	16.7	275
66	Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. <i>Circulation</i> , 1997 , 96, 856-63	16.7	219
65	Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. <i>Circulation</i> , 1997 , 96, 1501-6	16.7	60
64	Acute decompensated heart failure update. Current Cardiology Reviews, 2015, 11, 53-62	2.4	25
63	Herzinsuffizienz. 2000 , 319-330		

(2009-2000)

62	Inotropic and Vasopressor Agents. 2000 , 194-214		
61	The Future of Heart Failure Management. 2001 , 131-143		
60	Besonderheiten der Herzinsuffizienz bei Frauen. 2002 , 192-207		
59	Digitalis and Diuretics. 2002 , 179-192		
58	Regulation of Digitalis Glycoside Receptors in Digoxin Treatment. <i>Progress in Experimental Cardiology</i> , 2003 , 501-510		
57	[Back to the future: pathophysiology and therapeutic strategies in heart failure]. <i>Journal of Nippon Medical School</i> , 2004 , 71, 421-5	1.3	
56	Diuretics and Digitalis. 2005 , 181-194		
55	Clinical significance of therapeutic drug monitoring in pharmacotherapy rationalization and individualization. <i>Kontakt</i> , 2005 , 7, 211-218	0.3	
54	Hoe denkt men tegenwoordig over de therapie met digoxine?. 2006, 37-39		
53	Inotropic Therapy in Heart Failure Management. Fundamental and Clinical Cardiology, 2006, 137-154		
52	Acute Heart Failure. Fundamental and Clinical Cardiology, 2006, 203-226		
51	Congestive Heart Failure: Epidemiology, Pathophysiology, and Current Therapies. <i>Fundamental and Clinical Cardiology</i> , 2006 , 525-544		
50	Update in the approach to and management of heart failure. Southern Medical Journal, 2006, 99,	0.6	3
	1346-55; quiz 1356-7, 1384	0. 0	
49	Pharmacologic Management of Heart Failure in the Ambulatory Setting. 2007 , 331-362		
49 48			
	Pharmacologic Management of Heart Failure in the Ambulatory Setting. 2007 , 331-362		
48	Pharmacologic Management of Heart Failure in the Ambulatory Setting. 2007, 331-362 The Medical Management of Heart Failure. 2007, 1397-1416		

44	HEART FAILURE. 2009 , 389-399		
43	The Pharmacologic Management of Heart Failure. 2010 , 883-902		
42	Evidence-Based Management of the Patient with Congestive Heart Failure. 2011 , 497-518		
41	Digitalis. 2011 , 1317-1321		
40	Diuretics, digitalis, and electrolytes. 2011 , 277-284		
39	Vasoactive Drugs in Acute Care. 2014 , 73-200		Ο
38	Chronische Herzinsuffizienz. 1995 , 119-143		
37	Therapie der Herzinsuffizienz. 1996 , 1157-1213		
36	Cardiovascular Complications in Uremia and Dialysis. 1998 , 817-839		
35	Treatment of Congestive Heart Failure in the Elderly. 1998 , 145-152		
34	Molekulare Grundlagen der Herzinsuffizienz. 1998 , 147-221		Ο
33	Congestive Heart Failure. Developments in Cardiovascular Medicine, 1999, 211-223		
32	1. Clinical Pharmacology in Heart Failure. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2015 , 46, 83-88	Ο	1
31	Adjunct Therapy and Calcium Channel Blockers. <i>Respiratory Medicine</i> , 2015 , 303-321	0.2	
30	¿Tienen un rol los digitŪcos en la insuficiencia card∃ca crBica?. <i>Medwave</i> , 2015 , 15, e6129-e6129	2.5	
29	Is there a role for digitalis in chronic heart failure?. <i>Medwave</i> , 2015 , 15, e6129	2.5	1
28	[Treatment of chronic heart failure: is deprescribing possible?]. Kardiologiya, 2020, 60, 126-136	1.5	
27	Heart Failure IPathophysiology and Current Therapeutic Implications. <i>International Journal of Cardiovascular Sciences</i> , 2020 , 33, 439-446	0.4	

26	Closing the Digitalis Divide: Back to the Basics of Randomized Controlled Trials. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	
25	Chronische Herzinsuffizienz. 2006 , 217-335		
24	Outpatient management of congestive heart failure. Texas Heart Institute Journal, 1998, 25, 238-50	0.8	1
23	The economics of cardiac failure. <i>Journal of the Royal Society of Medicine</i> , 1996 , 89, 9-12	2.3	2
22	To dig or not to dig. <i>Transactions of the American Clinical and Climatological Association</i> , 1998 , 109, 51-6	10.9	
21	Clinical and Therapeutic Profiles of Heart Failure Patients admitted to a Tertiary Hospital, Aseer Region, Saudi Arabia. <i>Sultan Qaboos University Medical Journal</i> , 2011 , 11, 230-5	0.9	5
20	Management of Patients Admitted with Acute Decompensated Heart Failure. <i>Ochsner Journal</i> , 2015 , 15, 284-9	1.5	3
19	Digoxin toxicity: Case for retiring its use in elderly patients?. Canadian Family Physician, 2016, 62, 223-8	0.9	7
18	Heart Failure: A Class Review of Pharmacotherapy. P and T, 2017, 42, 464-472	1.4	6
17	Pharmakotherapie: Kann man Digitalis noch verordnen?.		
16	Comparison of heart rate and symptoms in two different methods of digoxin prescription. <i>Journal of Cardiology & Current Research</i> , 2021 , 14, 119-124	0.1	
15	Digoxin Impact on Heart Failure Patients with Atrial Fibrillation <i>Medicinski Arhiv = Medical Archives = Archives De M</i> decine, 2022 , 76, 23-28	1.2	
14	Optimal effectiveness of heart failure management - an umbrella review of meta-analyses examining the effectiveness of interventions to reduce (re)hospitalizations in heart failure <i>Heart Failure Reviews</i> , 2022 , 1	5	2
13	Chronic Digoxin Toxicity Leading to Institutionalization of an Elderly Woman <i>Canadian Journal of Hospital Pharmacy</i> , 2022 , 75, 118-121	0.5	О
12	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines <i>Circulation</i> , 2022 , 101161CIR0000000000001063	16.7	35
11	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines <i>Journal of the American College of Cardiology</i> , 2022 ,	15.1	49
10	Synthesis and Biological Activity of the Pyridine-Hexacyclic-Steroid Derivative on a Heart Failure Model <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2021 ,	2	О
9	Digoxin Use in Atrial Fibrillation; Insights from National Ambulatory Medical Care Survey <i>Current</i>	17.1	

8	Current evidence for pharmacologic therapy following stage 1 palliation for single ventricle congenital heart disease. <i>Expert Review of Cardiovascular Therapy</i> ,	2.5
7	Cardiology 1999; Review of the Withering Bicentenary Symposium Held in the College on 5 February 1999. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2000 , 30, 58-62	0.9
6	Digoxin and Outcomes in Patients with Heart Failure and Preserved Ejection Fraction [HFpEF] Patients: A Systematic Review and Meta-analysis. 2022 , 23,	1
5	CURRENT TRENDS IN THE MANAGEMENT OF HEART FAILURE. 2000 , 35, 855-875	1
4	Whither digitalis? What we can still learn from cardiotonic steroids about heart failure and hypertension.	О
3	Acute Heart Failure: DiagnosticTherapeutic Pathways and Preventive Strategies A Real-World Clinician Guide. 2023 , 12, 846	1
2	Two New Secondary Metabolites Isolated from the Fungus Penicillium Virgatum 49-A.	O
1	Mapping the methodological diversity of published drug discontinuation studies∃ scoping review of study topics, objectives, and designs. 2023 , 24,	O